---
title: "LifeSci Capital Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286648505.md"
description: "LifeSci Capital analyst Rami Katkhuda has maintained a Buy rating on Amylyx Pharmaceuticals Inc (AMLX) with a price target of $24.00. Katkhuda, a 5-star analyst, has an average return of 30.9% and a success rate of 52.19%. Guggenheim also reiterated a Buy rating with a $30.00 price target."
datetime: "2026-05-16T14:36:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286648505.md)
  - [en](https://longbridge.com/en/news/286648505.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286648505.md)
---

# LifeSci Capital Remains a Buy on Amylyx Pharmaceuticals Inc (AMLX)

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of $24.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Katkhuda is a 5-star analyst with an average return of 30.9% and a 52.19% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Viridian Therapeutics, and Dianthus Therapeutics.

In a report released on May 11, Guggenheim also reiterated a Buy rating on the stock with a $30.00 price target.

### Related Stocks

- [AMLX.US](https://longbridge.com/en/quote/AMLX.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VRDN.US](https://longbridge.com/en/quote/VRDN.US.md)
- [DNTH.US](https://longbridge.com/en/quote/DNTH.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus](https://longbridge.com/en/news/286360144.md)
- [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md)